---
document_datetime: 2024-03-04 14:50:51
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zyclara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zyclara-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.4978892
conversion_datetime: 2025-12-19 14:11:58.803014
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zyclara

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0032               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 29/02/2024                          |                                             | PL                               |                                   |
| PSUSA/1729/ 202301   | Periodic Safety Update EU Single assessment - imiquimod                                          | 28/09/2023                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0030   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/07/2023   |            | Annex II and PL            |                                                                                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|-----------------------------------------------------------------------------------------------------|
| T/0028    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/10/2022   | 02/12/2022 | SmPC and PL                |                                                                                                     |
| N/0027    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 07/12/2021   | 28/03/2022 | PL                         |                                                                                                     |
| IB/0026   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/07/2021   | 28/03/2022 | SmPC                       | To reduce the shelf-life of the finished product as packaged for sale, from 30 months to 18 months. |
| IA/0025/G | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 16/04/2021   | n/a        |                            |                                                                                                     |
| IA/0024   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/03/2021   | 28/03/2022 | Annex II, Labelling and PL |                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0023            | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/01/2021   | n/a        |                 |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1729/ 202001 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/10/2020   | 14/12/2020 | PL              | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1729/202001. |
| IB/0021/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 25/06/2020   | 14/12/2020 | Annex II and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|             | - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits   |            |     | B.II.b.2.c.1   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| IA/0020/G   | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                     | 14/08/2019 | n/a |                |
| IAIN/0018/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 21/11/2018 | n/a |                |

<div style=\"page-break-after: always\"></div>

|         | manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0017  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/08/2018 | 25/02/2019 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0016 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                              | 16/02/2018 | 25/02/2019 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0013 | Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to add information from study X-03016-3284 (LEIDA 2) and from a meta-analysis of studies X- 03016-3271 and X-03016-3284, two open-label randomized, controlled studies investigating the long-term effects of imiquimod 5% (and not with this 3.75% product) in comparison to topical diclofenac (3% gel). The MAH took the opportunity to update the details of local representatives in the PL. C.I.2.b - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 09/11/2017 | 11/12/2017 | SmPC and PL | One additional 2-week treatment of Zyclara may be considered in case lesions do not respond completely to treatment at 8 weeks after the second treatment cycle. A different therapy is recommended if the treated lesions show insufficient response to Zyclara. Also, that actinic keratosis (AK) lesions that have cleared after two Zyclara treatment cycles of 2 weeks and subsequently recur can be re-treated with one or two further Zyclara treatment cycles of 2 weeks following an at least 12 weeks treatment pause. Two open-label randomized, controlled studies investigated the long-term effects of imiquimod 5% (and not with this 3.75% product) in comparison to topical diclofenac (3% gel). These studies showed that imiquimod was better than |

<div style=\"page-break-after: always\"></div>

|                    | product - Change(s) require to be further substantiated by new additional data to be submitted by the MAH                                                                                                                                    |            |            |                                  | topical diclofenac in preventing the histological progression of AK lesions to in-situ or invasive squamous cell carcinoma (SCC). In addition, these studies supported the use of up to two additional treatment cycles of imiquimod when the AK lesions are not completely cleared or if the AK lesions recurred after successful initial treatment with imiquimod.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1729/ 201701 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                                                      | 28/09/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                      |
| IA/0014            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 11/05/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                        |
| R/0012             | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 26/01/2017 | 22/03/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zyclara in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                  |
| N/0011             | Update of the package leaflet with revised contact details of the local representatives for Italy, Spain and France. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                        | 27/06/2016 | 22/03/2017 | PL                               |                                                                                                                                                                                                                                                                                                                                                                        |
| N/0010             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 04/09/2015 | 02/12/2015 | PL                               |                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0009            | B.II.d.2.e - Change in test procedure for the finished product - Update of the test procedure to comply with the updated general monograph in the Ph. Eur.                                                     | 27/04/2015   | n/a        |                                  |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| IB/0008            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                 | 16/12/2014   | 02/12/2015 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/1729/ 201401 | Periodic Safety Update EU Single assessment - imiquimod                                                                                                                                                        | 11/09/2014   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0007            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                           | 24/06/2014   | n/a        |                                  |                                   |
| N/0005             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                               | 26/09/2013   | 02/12/2015 | PL                               |                                   |
| IG/0277            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                 | 26/03/2013   | n/a        |                                  |                                   |
| IB/0002            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | 21/01/2013   | n/a        |                                  |                                   |
| IB/0003/G          | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.c.2.d - Change in test procedure for an excipient | 14/12/2012   | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|         | - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                  | 07/12/2012 | n/a |